[go: up one dir, main page]

JPS6026387B2 - Cinnamyl moranoline derivative - Google Patents

Cinnamyl moranoline derivative

Info

Publication number
JPS6026387B2
JPS6026387B2 JP571479A JP571479A JPS6026387B2 JP S6026387 B2 JPS6026387 B2 JP S6026387B2 JP 571479 A JP571479 A JP 571479A JP 571479 A JP571479 A JP 571479A JP S6026387 B2 JPS6026387 B2 JP S6026387B2
Authority
JP
Japan
Prior art keywords
compound according
group
cinnamyl
moranoline
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP571479A
Other languages
Japanese (ja)
Other versions
JPS5598163A (en
Inventor
進午 松村
宏 榎本
良明 青柳
義明 吉国
紘平 倉
政広 八木
一朗 白波瀬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Shinyaku Co Ltd
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Priority to JP571479A priority Critical patent/JPS6026387B2/en
Priority to GB7909865A priority patent/GB2020278B/en
Priority to DE2915037A priority patent/DE2915037C3/en
Priority to FR7910559A priority patent/FR2424910A1/en
Priority to US06/033,839 priority patent/US4533668A/en
Priority to DK178379A priority patent/DK151623C/en
Priority to NLAANVRAGE7903421,A priority patent/NL175820C/en
Priority to SE7903817A priority patent/SE436874B/en
Priority to IT48904/79A priority patent/IT1116820B/en
Priority to CH415879A priority patent/CH642629A5/en
Publication of JPS5598163A publication Critical patent/JPS5598163A/en
Priority to AT278781A priority patent/AT371441B/en
Priority to SE8402549A priority patent/SE451015B/en
Priority to SE8402551A priority patent/SE451017B/en
Priority to SE8402550A priority patent/SE451016B/en
Publication of JPS6026387B2 publication Critical patent/JPS6026387B2/en
Expired legal-status Critical Current

Links

Landscapes

  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

【発明の詳細な説明】 本発明者らは先に湊薬「桑白皮」中より下の〔B〕式中
Z=日で表わされる物質を天然界より初めて発見単離し
、モラノリンと命名し、報告した。
DETAILED DESCRIPTION OF THE INVENTION The present inventors previously discovered and isolated the substance represented by Z=day in the formula [B] below in the minato drug "Mulberry Peel" from the natural world, and named it moranolin. ,reported.

(八木ら:日本農芸化学会誌、5項萱、571頁、(1
976年))。その後本発明者らはモラノリンの生理作
用について研究を重ねた結果モラノリンが糖負荷動物の
皿槍上昇を抑制するという医薬品として極めて有用な作
用を有している事を発見し、モラノリンを主成分とする
血糖上昇抑制剤を発明するに至り、特許出願した。
(Yagi et al.: Journal of the Japanese Society of Agricultural Chemistry, Section 5, 571 pages, (1
976)). Subsequently, the present inventors conducted repeated research on the physiological effects of moranolin, and discovered that moranolin has an extremely useful action as a pharmaceutical drug, suppressing the rise in blood pressure in sugar-loaded animals. Invented a blood sugar increase suppressant and applied for a patent.

その後本発明者らはモラノリンの新規な各種誘導体につ
いて研究を続行した結果、モラノリンと比較してはるか
に強力な活性を有する−群の新規なモラノリン議導体を
発見するに至り、本発明を完成した。
After that, the present inventors continued their research on various new derivatives of moranoline, and as a result, they discovered a new molanolin derivative of the - group, which has much stronger activity than moranoline, and completed the present invention. .

本発明に含まれる化合物は何れも新規化合物であり、構
造的にはN−シンナミルモラノリン譲導体とみなす事が
できる。
All of the compounds included in the present invention are new compounds, and can be structurally considered to be N-cinnamyl moranoline derivatives.

モラノリンの各種のN−アラルキル又はアラルケニル誘
導体の血糖上昇抑制活性は、芳香核とモラノリンの窒素
原子との間の炭素鎖数に大きく依存しており、炭素鎖数
1および2の場合は全く活性を示さず、炭素鎖数3以上
ではじめて活性を示す。競中炭素鎖数3,4の場合に長
大の活性を示し、特ににN−シンナミルモラノリンの活
性は極めて強い。又、シンナミル基のy位に鷹換基を有
する例えばyーメチルシンナミル、yーエチルシンナミ
ル譲導体等はシンナミル議導体と同等に活性があり、又
、芳香核上に各種のァルコキシ基を置換基として有する
シンナミル誘導体は一般的に高活性である。
The hypoglycemic activity of various N-aralkyl or aralkenyl derivatives of moranoline largely depends on the number of carbon chains between the aromatic nucleus and the nitrogen atom of moranoline, and those with one or two carbon chains have no activity at all. It shows activity only when the number of carbon chains is 3 or more. It shows a long activity when the number of carbon chains is 3 or 4, and the activity of N-cinnamyl moranoline is particularly strong. In addition, y-methylcinnamyl, y-ethylcinnamyl derivatives, etc., which have a hawk substituent group at the y-position of the cinnamyl group, are as active as cinnamyl derivatives, and also have various alkoxy groups on the aromatic nucleus. Cinnamyl derivatives used as substituents generally have high activity.

鎚中、本発明に含まれるグリコールェーテル型置換基を
有する化合物は高活性でしかも低毒性であり、医薬品と
して特に有用である。これらのグリコールェーテル型瞳
換基を有するシンナミル誘導体として本発明に含まれる
物質以外に炭素数1から18の各種のアルコキシ置換基
を有するェトキシ基又はプロポキシ基を有するシンナミ
ル誘導体が含まれる。又これらのグリコールェーテル型
贋襖基を2ケ以上有するものもあり、又道襖位値による
数多くの異性体が存在するのは勿論である。本発明に含
まれる物質の有する有用な生理作用はこれらのグリコー
ルェーテル型シンナミルモラノリン誘導体に一般的に存
在する性質であり、本発明に含まれる物質のみに限定さ
れたものではない。さて、本発明に含まれる置換シンナ
ミルモラノリン譲導体は何れもモラノリンと比較しては
るかに強力な活性を有するのみならず、Nーアルキルモ
ラノリン類や無置換のシンナミルモラ/リンと比較して
もより一層強い活性を有している。
In particular, the compounds having glycol ether type substituents included in the present invention have high activity and low toxicity, and are particularly useful as pharmaceuticals. In addition to the substances included in the present invention, cinnamyl derivatives having glycol ether-type pupil substituents include cinnamyl derivatives having ethoxy groups or propoxy groups having various alkoxy substituents having 1 to 18 carbon atoms. In addition, some compounds have two or more of these glycol ether-type groups, and it goes without saying that there are many isomers based on their positional values. The useful physiological effects of the substances included in the present invention are properties that generally exist in these glycol ether type cinnamyl moranoline derivatives, and are not limited to the substances included in the present invention. Now, all of the substituted cinnamylmoranoline derivatives included in the present invention not only have much stronger activity than moranoline, but also have much stronger activity than N-alkylmoranolines and unsubstituted cinnamylmoranoline/phosphorus. It has even stronger activity.

第1表に本発明に含まれる代表的な物質の活性とN−ペ
ンジルモラノリン、Nーフエネチルモラノリン、N一シ
ンナミルモラノリン、およびモラノリン、Nーメチルモ
ラノリンの活性を比較して示す。活性は被検物質1雌/
koを庶糖被/k9と同時にラットに経口投与した場合
の、120分後の血糖上昇をコントロール群と比較し、
その抑制率で表わす。第 1 表 このように、本発明に含まれる物質はいずれも強い血機
上昇抑制作用を有しており、人間および動物の過血糖症
状および縄血糖に起因する種々の疾患、例えば糖尿病、
動脈硬化症、肥満、胃炎、胃濃湯、十二指腸濃蕩等の予
防および治療薬として極めて有用である。
Table 1 compares the activities of representative substances included in the present invention with those of N-penzylmolanoline, N-phenethylmoranoline, N-cinnamylmolanoline, and moranoline, N-methylmoranoline. show. Activity is test substance 1 female/
When ko was orally administered to rats at the same time as sucrose/k9, the increase in blood sugar after 120 minutes was compared with the control group.
It is expressed as the suppression rate. Table 1 As described above, all the substances included in the present invention have a strong effect of suppressing blood elevation, and are effective against hyperglycemic symptoms and various diseases caused by blood sugar in humans and animals, such as diabetes,
It is extremely useful as a prophylactic and therapeutic agent for arteriosclerosis, obesity, gastritis, gastric hyperplasia, duodenal hyperplasia, etc.

さて、本発明に含まれる化合物は何れもN−置換シンナ
ミル誘導体であり、アミン類のNーアラルケニル化反応
に一般的に使用し得る各種の合成法により合成する事が
できる。
All of the compounds included in the present invention are N-substituted cinnamyl derivatives, and can be synthesized by various synthetic methods commonly used for N-aralkenylation reactions of amines.

即ち活性化置換シンナミル基を有する化合物例えば置換
シンナミルハライド、同じくスルフオネート、フオスフ
ヱート等を使用する通常の求咳置換反応による方法や置
換シンナムアルデヒドを使用するいわゆる還元的ァルキ
ル化反応等が一般に有利に実施し得る。又、直予期陣皮
酸等とのアミド型化合物とした後にカルボニル基を還元
して目的物を得る方法によっても合成可能である。これ
らの反応の一方の原料としてはモラノリンそのものを使
用できる事は勿論であるがモラノリン水酸基を適当な保
護基、例えばアセチル基、ベンゾィル基、ベンジル基、
テトラヒドロピラニル基等で保護した中間体を使用し、
N置換反応を行なった後に保護基を除去して目的物を得
る事もできる。又、化合物5,7で代表されるような、
芳香環上の置換基に水酸基を有するような化合物は、上
述した方法による合成法の他に、まずフェ/ール性水酸
基を有する中間体を合成し、しかる後にアルカリ性条件
下でエチレンオキサィドやグリシドールのごときェポキ
シ試薬と反応させて合成する事ができる。以下実施例に
より、本発明に含まれる代表的化合物につき、その合成
法の一例を述べる。
That is, a conventional cough substitution reaction using a compound having an activated substituted cinnamyl group, such as a substituted cinnamyl halide, sulfonate, phosphonate, etc., or a so-called reductive alkylation reaction using a substituted cinnamaldehyde, etc. are generally advantageously carried out. It is possible. Alternatively, it can be synthesized by a method in which the desired compound is obtained by forming an amide type compound with a directly expected cinnamic acid, etc., and then reducing the carbonyl group. Of course, moranoline itself can be used as a raw material for one of these reactions, but the hydroxyl group of moranoline can be protected by an appropriate protecting group, such as an acetyl group, benzyl group, benzyl group, etc.
Using intermediates protected with tetrahydropyranyl groups,
The desired product can also be obtained by removing the protecting group after performing the N-substitution reaction. In addition, as represented by compounds 5 and 7,
Compounds having a hydroxyl group as a substituent on an aromatic ring can be synthesized in addition to the above-mentioned method by first synthesizing an intermediate having a phenolic hydroxyl group, and then synthesizing it with ethylene oxide under alkaline conditions. It can be synthesized by reacting with an epoxy reagent such as or glycidol. In the following, an example of a method for synthesizing typical compounds included in the present invention will be described with reference to Examples.

実施例 1 化合物1の合成 m−オキシベンッアルデヒドをDMF中無水炭酸カリウ
ム存在下、メトキシェトキシプロマィドと反応して得ら
れるm−B−メトキシェトキシベンッアルデヒド12.
7gを無水テトラヒドロフラン50の‘に溶解し、ビニ
ルマグネシウムブロミド約2次を含む無水テトラヒドo
フラン溶液中に氷冷燈梓下滴下。
Example 1 Synthesis of Compound 1 m-B-methoxybentaldehyde obtained by reacting m-oxybennaldehyde with methoxyethoxybromide in the presence of anhydrous potassium carbonate in DMF 12.
Dissolve 7 g of anhydrous tetrahydrofuran in 50' of anhydrous tetrahydrofuran containing about 20% vinylmagnesium bromide.
Drop ice cold light into the furan solution.

滴下後30分間室温で燈拝し、以後常法により処理して
無色油状のカルビノール型化合物12.鍵を得る。上に
得られたカルビノール化合物1後をェーナル50の‘に
熔解し、氷冷輝梓下、三臭化燐8.1gを加え5分間燈
拝。
After the dropwise addition, it was left to stand at room temperature for 30 minutes, and then treated by a conventional method to obtain a colorless oily carbinol type compound 12. Get the key. The carbinol compound 1 obtained above was melted in 50' of water, cooled with ice, 8.1 g of phosphorus tribromide was added, and the mixture was heated for 5 minutes.

冷水100叫を加えて水洗後ェーナル層を無水硫酸マグ
ネシウムで乾燥し、減圧下30℃以下でエーテルを蟹去
。淡黄色油状のシンナミルフロマィド誘導体1唆を得る
。一方、モラノリン3雌をエチレングリコール50の上
に溶解し、重炭酸ナトリウム5.舷を加え、室温縄梓下
、上に得られたシンナミルプロマィド誘導体を約20分
間で加え、室温で3時間蝿拝する。
After washing with 100 ml of cold water, the ether layer was dried over anhydrous magnesium sulfate, and the ether was removed under reduced pressure at 30°C or less. A pale yellow oily cinnamyl furomide derivative was obtained. Meanwhile, 30% of moranolin was dissolved in 50% of ethylene glycol and 50% of sodium bicarbonate. Add the cinnamyl bromide derivative obtained above for about 20 minutes under a rope at room temperature, and stir at room temperature for 3 hours.

反応後反応液を水で希釈し、塩酸酸性としてエーテルで
洗総した後アンモニアアルカリ性としnーブタノールで
抽出。ブタノールを留去し、残留する結晶性物質をィソ
ブロパノール−メタノール混合溶媒で再結晶。収量な.
1g。
After the reaction, the reaction solution was diluted with water, acidified with hydrochloric acid, washed with ether, made alkaline with ammonia, and extracted with n-butanol. Butanol was distilled off, and the remaining crystalline material was recrystallized from a mixed solvent of isopropanol and methanol. Yield.
1g.

融点136〜1斑℃。〔Q〕色4=−39.70(メタ
ノール)実施例 2 化合物2の合成 m−オキシアセトフエノンとメトキシエトキシフロマイ
ドとより製したm−Bーメトキシェトキシアセトフェノ
ンを実施例1と同様にグリニア反応に付し、得られるカ
ルビノール化合物14錐をエーテル50の【中氷冷下三
臭化燐9.彼と5分間処理し、シンナミルフロマィド型
物質16.処を得る。
Melting point: 136-1°C. [Q] Color 4 = -39.70 (methanol) Example 2 Synthesis of Compound 2 m-B-methoxyethoxyacetophenone prepared from m-oxyacetophenone and methoxyethoxyfuromide was prepared in the same manner as in Example 1. The resulting carbinol compound (14) was subjected to a Grignard reaction, and the resulting carbinol compound was mixed with ether (50%) and phosphorus tribromide (9%) under ice-cooling. Treat with him for 5 minutes, cinnamylfuromide type substance 16. get a place

モラノリン3.1gをDMS050の‘に溶解し、重炭
酸ナトリウム5.雌を加え、上に得られたべロマィド1
賭を室温燈梓下1.虫時間で滴下。滴下後30分間縄梓
。以下実施例1と同機に処理し、ブタノール抽出物をイ
ソプロパノールと処理すれば結晶化。エタノールより再
結晶。収量3.1総。融点116〜119℃。〔Q〕容
=一弘.90(メタ/−ル)実施例 3 化合物3の合成 pーオキシベンッアルデヒドを出発原料とし実施例1と
同様に反応し、得られるブロマイド7.1gをモラノリ
ン3を、重炭酸ナトリウム3.笹とDMS030地中室
温で1時間燈梓反応、以下実施例1と同様に処理し、得
られるブタノール抽出物をエタノールより再結晶。
Dissolve 3.1 g of moranoline in DMS050' and 5.1 g of sodium bicarbonate. Add the female and the obtained belomide 1 on top
Bet on the room lamp Azusa 1. Drips in insect time. Rope Azusa for 30 minutes after dripping. The following treatment was carried out in the same manner as in Example 1, and the butanol extract was treated with isopropanol to crystallize. Recrystallized from ethanol. Yield 3.1 total. Melting point 116-119°C. [Q] Yong = Kazuhiro. 90 (meth/-) Example 3 Synthesis of Compound 3 Using p-oxybenaldehyde as a starting material, the reaction was carried out in the same manner as in Example 1, and 7.1 g of the resulting bromide was mixed with 3 moranolin and 3.0 g of sodium bicarbonate. Bamboo and DMS030 were reacted underground at room temperature for 1 hour, followed by the same treatment as in Example 1, and the resulting butanol extract was recrystallized from ethanol.

収量1.斑&融点1ね〜I74℃。Yield 1. Spots & melting point 1~I74℃.

〔Q〕色4=−48.60(メタノール)実施例1,2
,3と同様の方法により化合物4,6を合成した。
[Q] Color 4 = -48.60 (methanol) Examples 1 and 2
, 3 were used to synthesize compounds 4 and 6.

化合物4 融点166〜16斬0 〔Q〕。Compound 4 Melting point 166-160 [Q].

24=−43r(メタノ ール) 化合物6 鷲&点118〜12ro 〔Q〕色4=−37‐70(メタノ ール) 実施例 4 化合物5,7の合成 pーオキシベンツアルデヒド2略をDMF200の‘に
溶解し、無水炭酸カリウム4巡、8−メトキシェトキシ
メチルクロラィド45gを加えて室温3時間燈梓。
24 = -43r (methanol) Compound 6 Eagle & Point 118-12ro [Q] Color 4 = -37-70 (methanol) Example 4 Synthesis of compounds 5 and 7 Dissolve p-oxybenzaldehyde 2 in DMF 200' Then, 4 cycles of anhydrous potassium carbonate and 45 g of 8-methoxyethoxymethyl chloride were added, and the mixture was heated at room temperature for 3 hours.

水で希釈し、エーテル抽出し、抽出物を減圧蒸留。b.
p.150〜15チ0/5岬Hgの留分2鬼を得る。こ
れを実施例1,2,3と同機ビニルマグネシウムプロマ
ィドとグリニア反応に付し、得られるカルピノール化合
物をエーテル中一10qoでチオニルクロライドの当モ
ル量と1分間処理してシンナミルクロラィド型化合物と
し実施例2,3と同様にDMSO中重炭酸ナトリウム存
在下モラノリンと反応してp−8ーメトキシェトキシメ
トキシシンナミルモラノリンを得る。融点111〜11
4午0。上に得られた結晶5彼をメタノール50の‘に
溶解し、濃塩酸2M、水5私を加え、2.虫時間加熱還
流。反応物を減圧下乾固し、残留物をエーテルで洗総し
、不溶物をエタノール−酢酸エチル混合溶媒で処理すれ
ば結晶化。収量3.Xg(pーハィドロキシシンナミル
モラノリン塩酸塩)化合物5の合成 上に得られた粗結晶1.雌を苛性カリウム1.雌を含む
メタノール30の‘に溶解し、エチレンオキサィド2の
‘を加えて、封管中8び0で3時間加熱。
Dilute with water, extract with ether, and distill the extract under reduced pressure. b.
p. Obtain 2 demons of distillate of 150-15 chi 0/5 Cape Hg. This was subjected to a Grignard reaction with the same vinyl magnesium bromide as in Examples 1, 2, and 3, and the resulting carpinol compound was treated with an equimolar amount of thionyl chloride in 10 qo in ether for 1 minute to form cinnamyl chloride. This compound is reacted with moranoline in DMSO in the presence of sodium bicarbonate in the same manner as in Examples 2 and 3 to obtain p-8-methoxyshethoxymethoxycinnamyl moranoline. Melting point 111-11
04:00. Dissolve the crystals obtained above in 50% methanol, add 2M concentrated hydrochloric acid and 5% water; 2. Heat to reflux for an hour. The reaction product was dried under reduced pressure, the residue was washed with ether, and the insoluble matter was treated with a mixed solvent of ethanol and ethyl acetate to crystallize. Yield 3. Crude crystals obtained in the synthesis of Xg (p-hydroxycinnamyl moranoline hydrochloride) compound 5 1. Females were treated with caustic potassium 1. Dissolve the solution in 30' of methanol, add 2' of ethylene oxide, and heat in a sealed tube at 8 to 0 for 3 hours.

反応物を減圧下乾固し、残留物を水に溶解してイオン交
側樹脂ダウェックス50Wx4(日型)のカラムに通じ
る。カラムを水洗後、アンモニア1%を含む50%含水
メタノールで吸着物を溶出し、溶出液を減圧下乾団し、
残留する淡黄色粘稲油状の反応物にp−トルヱンスルホ
ン酸0.舷を加えィソプロパノールと処理すれば結晶化
。エタノールより再結晶。収量0.8を、融点131〜
1松℃。〔Q〕多=−29.60(メタノール)化合物
7の合成 先に得らた粗製のpーハィドロキシシンナミルモラノリ
ン塩酸塩1.咳をメタノール30の‘に溶解し、苛性カ
リウム1.雌を加え、グリシドール2の【加えて4時間
加熱還流。
The reaction product was dried under reduced pressure, and the residue was dissolved in water and passed through a column of ion-exchange resin DOWEX 50Wx4 (Japanese model). After washing the column with water, the adsorbate was eluted with 50% aqueous methanol containing 1% ammonia, and the eluate was evaporated under reduced pressure.
Add 0.0% p-toluenesulfonic acid to the remaining pale yellow sticky oil-like reaction product. It crystallizes when added to the hull and treated with isopropanol. Recrystallized from ethanol. Yield 0.8, melting point 131~
1 pine ℃. [Q] poly=-29.60 (methanol) Crude p-hydroxycinnamyl moranoline hydrochloride obtained before synthesis of compound 7 1. Dissolve the cough in 30' of methanol and 1.0' of caustic potassium. Add females, add glycidol 2 and heat under reflux for 4 hours.

以後化合物5の場と同機に処理し、得られる反応物をp
ートルェンスルホン酸塩としイソプoパノールより再結
晶。収量0.81g。融点126〜130q○。〔Q〕
歓=一25‐80 実施例 5 化合物3の合成 テトラ−○ーベンジルモラノリン(融点44〜46℃、
〔Q〕容=3が(エタノール))5.滋をDM『30叫
に溶解。
Thereafter, compound 5 was treated in the same place and the resulting reaction product was
-Toluenesulfonate and recrystallized from isopropanol. Yield: 0.81g. Melting point 126-130q○. [Q]
Huan = 125-80 Example 5 Synthesis of compound 3 Tetra-○-benzylmolanoline (melting point 44-46°C,
[Q] Volume = 3 (ethanol))5. DM Shigeru ``Dissolved in 30 screams.

無水炭酸カリウム3.0gを加え、蝿梓下、実施例3で
述べたp−メトキシェトキシシンナミルフロマイド3.
咳を加えて60℃〜70qoで6時間加温燈梓。反応後
、反応液を水で希釈し、希塩酸酸性としn−へキサンで
洗総後、アンモニアアルカリ性としベンゼン抽出する。
ベンゼンを蟹去後残留する結晶性物質をそのまま24%
臭化水素酸50地と90〜9ず0で3時間処理。減圧下
乾団し、残留物を水に溶解し、エーテルで洗練後アンモ
ニアアルカリとしn−プタノール抽出。抽出物をシリカ
ゲルのカラム上クロロホルムーメタノール3:1混液で
カラムクロマト精製しエタノールより再結晶。収量1.
83チ融点172〜174℃。
3. Add 3.0 g of anhydrous potassium carbonate, and add p-methoxychetoxycinnamyl furomide described in Example 3 under Azusa.
Cough and heat at 60℃~70qo for 6 hours. After the reaction, the reaction solution was diluted with water, made acidic with dilute hydrochloric acid, washed with n-hexane, made alkaline with ammonia, and extracted with benzene.
24% of the crystalline substance remaining after removing benzene
Treated for 3 hours with hydrobromic acid 50% and 90-90%. The residue was dried under reduced pressure, dissolved in water, purified with ether, ammonia alkali, and extracted with n-butanol. The extract was purified by column chromatography on a silica gel column using a 3:1 mixture of chloroform and methanol, and then recrystallized from ethanol. Yield 1.
83, melting point 172-174°C.

Claims (1)

【特許請求の範囲】 1 次の一般式〔A〕で表わされる置換シンナミルモラ
ノリン誘導体およびその酸付加塩類。 ▲数式、化学式、表等があります▼ ここにR_1は水
素又はメチル基を、R_2は水素又はハイドロキシメチ
ル基を、R_3は水素、メチル基、エチル基又はメトキ
シエチル基を表わす。 2 R_1が水素である特許請求の範囲第1項記載の化
合物。 3 R_2が水素である特許請求の範囲第2項記載の化
合物。 4 R_3が水素である特許請求の範囲第3項記載の化
合物。 5 R_3がメチル基である特許請求の範囲第3項記載
の化合物。 6 R_3がエチル基である特許請求の範囲第3項記載
の化合物。 7 R_3がメトキシエチル基である特許請求の範囲第
3項記載の化合物。 8 R_2がハイドロキシメチル基である特許請求の範
囲第2項記載の化合物。 9 R_3が水素である特許請求の範囲第8項記載の化
合物。 10 R_1がメチル基である特許請求の範囲第1項記
載の化合物。 11 R_2が水素である特許請求の範囲第10項記載
の化合物。 12 R_2がメチル基である特許請求の範囲第11項
記載の化合物。
[Scope of Claims] 1. A substituted cinnamyl moranoline derivative represented by the following general formula [A] and acid addition salts thereof. ▲There are mathematical formulas, chemical formulas, tables, etc.▼ Here, R_1 represents hydrogen or a methyl group, R_2 represents hydrogen or a hydroxymethyl group, and R_3 represents hydrogen, a methyl group, an ethyl group, or a methoxyethyl group. 2. The compound according to claim 1, wherein R_1 is hydrogen. 3. The compound according to claim 2, wherein R_2 is hydrogen. 4. The compound according to claim 3, wherein R_3 is hydrogen. 5. The compound according to claim 3, wherein R_3 is a methyl group. 6. The compound according to claim 3, wherein R_3 is an ethyl group. 7. The compound according to claim 3, wherein R_3 is a methoxyethyl group. 8. The compound according to claim 2, wherein R_2 is a hydroxymethyl group. 9. The compound according to claim 8, wherein R_3 is hydrogen. 10. The compound according to claim 1, wherein R_1 is a methyl group. 11. The compound according to claim 10, wherein R_2 is hydrogen. 12. The compound according to claim 11, wherein R_2 is a methyl group.
JP571479A 1978-05-03 1979-01-20 Cinnamyl moranoline derivative Expired JPS6026387B2 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
JP571479A JPS6026387B2 (en) 1979-01-20 1979-01-20 Cinnamyl moranoline derivative
GB7909865A GB2020278B (en) 1978-05-03 1979-03-21 Moranoline dervitives
DE2915037A DE2915037C3 (en) 1978-05-03 1979-04-12 New N-substituted moranoline derivatives
FR7910559A FR2424910A1 (en) 1978-05-03 1979-04-25 MORANOLINE N-SUBSTITUTES DERIVATIVES AND THEIR USE, IN PARTICULAR FOR THE TREATMENT OF HYPERGLYCEMIA
US06/033,839 US4533668A (en) 1978-05-03 1979-04-27 Antihyperglycemic moranoline derivatives
DK178379A DK151623C (en) 1978-05-03 1979-05-01 METHOD OF ANALOGUE FOR THE PREPARATION OF N-SUBSTITUTED MORANOLINE DERIVATIVES OR PHARMACEUTICAL ACCEPTABLE ACID ADDITION SALTS.
SE7903817A SE436874B (en) 1978-05-03 1979-05-02 N-SUBSTITUTED MORANOLINE DERIVATIVES
NLAANVRAGE7903421,A NL175820C (en) 1978-05-03 1979-05-02 N-SUBSTITUTED MORANOLINE DERIVATIVES, METHOD FOR PREPARING A MEDICINAL PRODUCT THEREFROM, AND MEDICINAL PRODUCT OBTAINED THEREFORE.
IT48904/79A IT1116820B (en) 1978-05-03 1979-05-02 MORANOLINA DERIVATIVES WITH PHARMACOLOGICAL PROPERTIES
CH415879A CH642629A5 (en) 1978-05-03 1979-05-03 MORANOLINE DERIVATIVES SUBSTITUTED ON NITROGEN ATOM.
AT278781A AT371441B (en) 1979-01-20 1981-06-23 METHOD FOR PRODUCING NEW N-SUBSTITUTED MORANOLINE DERIVATIVES AND THEIR ACID ADDITION SALTS
SE8402549A SE451015B (en) 1978-05-03 1984-05-11 SUBSTITUTED MORANOLINE DERIVATIVES
SE8402551A SE451017B (en) 1978-05-03 1984-05-11 CINNAMYLMORANOLIN DERIVATIVES
SE8402550A SE451016B (en) 1978-05-03 1984-05-11 N-SUBSTITUTED MORANOLINE DERIVATIVES

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP571479A JPS6026387B2 (en) 1979-01-20 1979-01-20 Cinnamyl moranoline derivative

Publications (2)

Publication Number Publication Date
JPS5598163A JPS5598163A (en) 1980-07-25
JPS6026387B2 true JPS6026387B2 (en) 1985-06-24

Family

ID=11618779

Family Applications (1)

Application Number Title Priority Date Filing Date
JP571479A Expired JPS6026387B2 (en) 1978-05-03 1979-01-20 Cinnamyl moranoline derivative

Country Status (1)

Country Link
JP (1) JPS6026387B2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8827701D0 (en) * 1987-12-09 1988-12-29 Nippon Shinyaku Co Ltd Thrombolytic &c compositions
KR920703056A (en) * 1989-09-07 1992-12-17 아만 히데아키 Antiviral
US5252587A (en) * 1990-04-27 1993-10-12 Merrell Dow Pharmaceuticals, Inc. N-derivatives of 1-deoxy nojirimycin
US5536732A (en) * 1990-04-27 1996-07-16 Merrell Pharmaceuticals Inc. N-derivatives of 1-deoxy nojirimycin

Also Published As

Publication number Publication date
JPS5598163A (en) 1980-07-25

Similar Documents

Publication Publication Date Title
JPS582936B2 (en) 5↓-Production method of aroylpyrroleacetic acid and its salts
JPH0656724A (en) Production of new alkene derivative
SE451017B (en) CINNAMYLMORANOLIN DERIVATIVES
CH621329A5 (en)
EP0047536B1 (en) Substituted propylamines
SU1356960A3 (en) Method of producing derivatives of pyridazine
US3957850A (en) Phenylacetic acid derivatives
DD202012A5 (en) PROCESS FOR PREPARING 9-AMINO-1-HYDROXYOCTAHYDROBEZO (C) CHINOLINES AND THEIR DERIVATIVES
EP0155653B1 (en) Substituted (azacycloalk-2-yl) iminophenols and esters thereof
US4094987A (en) 2-(3-m-hydroxy-phenyl-1-substituted-3-pyrrolidinyl)-ethanols
NO773300L (en) PROCEDURE FOR THE PREPARATION OF NEW acetic acid derivatives
IE48065B1 (en) Alkanolamine derivatives,process for their preparation and pharmaceutical compositions containing them
JPS5845423B2 (en) Production method of new aminopropanol/derivatives
JPS6312063B2 (en)
JPS6026387B2 (en) Cinnamyl moranoline derivative
EP0087655A1 (en) Process for the preparation of acemetacin
KR100224330B1 (en) N- 4,5-dihydroxy- and 4,5,8-trihydroxy-9,10-dihydro-9,10-dioxo-2-anthracene-yl)carbonyl)amino acids
FR2503705A1 (en) PHENETHANOLAMINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
CH642941A5 (en) THERAPEUTICALLY EFFECTIVE 2-AMINOTETRALINE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF.
JPH0559117B2 (en)
JPS6312064B2 (en)
EP0000013B1 (en) 4-phenyl-8-amino-tetrahydroisoquinolines, pharmaceutical compositions containing them and process for preparation of these compositions
JPS5943946B2 (en) N-alkenylmoranoline derivative
Boekelheide et al. Curariform Activity and Chemical Structure. VIII. Lactones Derived from Quinolizidine1, 2
US4201790A (en) Benzophenone derivatives